Publication | Open Access

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

MedicineMelanomaImmunologyBrafv600k Mutation-positive MelanomaCancer TreatmentOpen-label StudyOncologyRadiation OncologyCancer ResearchNovel TherapyMolecular OncologyPhase 3